<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Deregulated c-MYC is found in a variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> where it promotes proliferation as well as <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="1" pm="."><plain>In many <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, enhanced NF-kappaB exerts prosurvival functions </plain></SENT>
<SENT sid="2" pm="."><plain>Here we investigated the role of NF-kappaB in mouse and human c-MYC-transformed <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>The NF-kappaB pathway is extinguished in murine <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells, and extrinsic stimuli typically inducing NF-kappaB activity fail to activate this pathway </plain></SENT>
<SENT sid="4" pm="."><plain>Genetic activation of the NF-kappaB pathway induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in these cells, whereas inhibition of NF-kappaB by an IkappaBalpha superrepressor provides a selective advantage in vivo </plain></SENT>
<SENT sid="5" pm="."><plain>Furthermore, in human Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells we find that NF-kappaB activation induces <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>NF-kappaB up-regulates Fas and predisposes to Fas-induced cell <z:hpo ids='HP_0011420'>death</z:hpo>, which is caspase-8 mediated and can be prevented by CFLAR overexpression </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that c-MYC overexpression sensitizes cells to NF-kappaB-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, and persistent inactivity of NF-kappaB signaling is a prerequisite for MYC-mediated <z:mp ids='MP_0002006'>tumorigenesis</z:mp> </plain></SENT>
<SENT sid="8" pm="."><plain>We could also show that low immunogenicity and Fas insensitivity of MYC-driven <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells are reversed by activation of NF-kappaB </plain></SENT>
<SENT sid="9" pm="."><plain>Our observations provide a molecular explanation for the described absence of the NF-kappaB signaling in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and question the applicability of NF-kappaB inhibitors as candidates for treatment of this <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
</text></document>